
    
      To determine the maximum tolerated dose of MB07133 when administered as a 7-day continuous
      i.v. To characterize the safety profile and the pharmacokinetics of MB07133 and metabolites
      during and after continuous infusion. To determine the effect of MB07133 on hepatocellular
      carcinoma (HCC) tumor size.
    
  